PolyPid (NASDAQ:PYPD) Stock Price Expected to Rise, HC Wainwright Analyst Says

PolyPid (NASDAQ:PYPD) had its price target hoisted by HC Wainwright from $11.00 to $13.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Separately, Roth Capital assumed coverage on shares of PolyPid in a research note on Thursday, June 5th. They issued a “buy” rating and a $9.00 target price on the stock. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, PolyPid currently has an average rating of “Buy” and a consensus price target of $11.25.

PolyPid Trading Up 2.8%

Shares of PYPD opened at $3.36 on Monday. PolyPid has a 1 year low of $2.30 and a 1 year high of $4.49. The company has a current ratio of 1.31, a quick ratio of 1.00 and a debt-to-equity ratio of 0.08. The stock has a 50 day simple moving average of $2.75 and a 200-day simple moving average of $2.91. The stock has a market cap of $34.24 million, a PE ratio of -0.68 and a beta of 1.25.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.10. On average, sell-side analysts predict that PolyPid will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PYPD. AIGH Capital Management LLC boosted its holdings in shares of PolyPid by 13.6% in the 1st quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock worth $2,548,000 after acquiring an additional 112,514 shares in the last quarter. J. Goldman & Co LP acquired a new stake in PolyPid during the 4th quarter valued at $391,000. Finally, Rosalind Advisors Inc. raised its position in PolyPid by 49.9% in the 4th quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after purchasing an additional 338,853 shares during the last quarter. Institutional investors own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.